The FDA has signed off on Celyad Oncology SA’s (NASDAQ:CYAD) IND for a Phase 1 clinical trial evaluating lead off-the-shelf short hairpin RNA-based allogeneic CAR-T candidate CYAD-211.
The study, in relapsed/refractory multiple myeloma patients, should launch by year-end.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.